安进Amgen Inc. (AMGN) 2023年年度报告「NASDAQ」.pdf

1、LETTER TOSHAREHOLDERS20232Amgen performed well in 2023,serving millions of patients around the world with our innovative,life-changing medicines;advancing many promising new first-in-class molecules in our pipeline;completing a significant acquisition that establishes us as a leader in treating rare

2、 diseases;and delivering strong financial performance.Our achievements last year favorably position Amgen to generate attractive growth through the end of the decade and beyond.Total revenues in 2023 increased 7%from the prior year to$28.2 billion,with non-GAAP earnings per share1 rising 5%to$18.65.

3、Demand for our medicines from patients and physicians was strong in 2023,resulting in 15%volume growth,partially offset by a 3%decline in net selling price.Eighteen medicines2 generated record sales in 2023,and nine had sales exceeding$1 billion.Product sales outside the U.S.were approximately$7.6 b

4、illion in 2023,up 8%,with especially strong growth coming from the Asia-Pacific region.We invested$4.8 billion in research and development in 2023,an increase of 8%from the prior year,to advance the broadest and deepest pipeline in our history.Amgen delivered total shareholder return of 13%in 2023 a

5、nd 232%over the past ten years,ahead of our peer set in both time frames.We increased our dividend per share by 10%in 2023 over 2022,the twelfth consecutive year of dividend increases.Our performance last year included$954 million in sales3 associated with our acquisition of Horizon Therapeutics plc

6、(Horizon),a leading provider of medicines to treat rare inflammatory diseases,which Amgen completed on October 6,2023,for approximately$27.8 billion.I will say more below about the medicines we acquired in this transaction.Broadly,the acquisition reflects our ongoing commitment to pursuing the best